Equillium stock analysis
Equillium (0FY) Stock Price & Analysis
0FY Stock Chart & Stats
- Day’s Range
- EUR 1.21 - EUR 1.23
- 52-Week Range
- EUR 0.69 - EUR 2.81
- Previous Close
- EUR 1.24
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 96.34M
- Enterprise Value
- EUR 129.32M
- Total Cash (Recent Filing)
- EUR 53.32M
- Total Debt (Recent Filing)
- EUR 765.00K
- Price to Earnings (P/E)
- ―
- Beta
- -1.33
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Minimal debt reduces financing pressure and preserves flexibility while Equillium funds clinical development. The increases in equity and assets versus 2025 provide a stronger capital base, although that base has not yet generated positive returns.
Extended Cash Runway
The additional capital gives Equillium a longer operating horizon to advance EQ504 and pursue planned studies without relying immediately on another financing. A runway extending into 2029 improves execution capacity and reduces near-term funding risk.
Clinical Pipeline Progress
Moving EQ504 into a controlled Phase 1 study is a meaningful development milestone because safety, pharmacokinetic, pharmacodynamic, and tissue-biomarker data can support later proof-of-concept work. This advances the pipeline beyond preclinical development.
Bears Say
Absent Recent Revenue
The complete absence of recent revenue weakens earnings visibility and shows that Equillium is not currently funding operations through commercial sales. Until revenue returns, financial progress remains dependent on clinical milestones and access to external capital.
Persistent Cash Burn
Sustained negative operating and free cash flow means the business consumes cash while advancing its pipeline rather than generating internal funding. Continued burn increases dependence on financing and can constrain development choices if capital access weakens.
Negative Shareholder Returns
A deeply negative return on equity indicates that the capital invested in Equillium is currently supporting losses rather than creating profitable output. Persistent negative returns can limit the company’s ability to compound value without successful clinical and commercial execution.
Equillium News
0FY FAQ
What was Equillium’s price range in the past 12 months?
What is Equillium’s market cap?
When is Equillium’s upcoming earnings report date?
How were Equillium’s earnings last quarter?
Is Equillium overvalued?
Does Equillium pay dividends?
What is Equillium’s EPS estimate?
How many shares outstanding does Equillium have?
What happened to Equillium’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Equillium?
What is the TipRanks Smart Score and how is it calculated?
Equillium Stock Smart Score
Company Description
Equillium
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bruce D. Steel
- Employees
- 14
- Website
- equilliumbio.com
- Address
- 2223 Avenida De La Playa, La Jolla, CA, 92037, US
Equillium (0FY) Earnings & Revenues
0FY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 1 | 0 | 11 |












